About Elkedonia
Major depression affects 332 million people. Most treatments rely on 50-year-old targets and fail one in three patients: a major unmet medical need. Elkedonia is developing a first-in-class treatment on a novel target, designed to act fast, durably and safely, without the hallucinations and addiction risk of ketamine and psychedelics. Patient data and biomarkers guide and derisk its clinical development. Backed by leading European life sciences investors, the company raised $13M in 2025.
Awarding Excellence Since 2017
We are proud to recognise an assortment of businesses, as each of our esteemed winners contribute to Europe's shifting corporate landscape in their own unique and innovative way.
Contact Us
Talk to our dedicated and professional Nominations Team for answers to any award-based questions you may have.
About The Award
The European CEO of the Year Awards proudly acknowledge and honour top-tier CEOs who have demonstrated exceptional leadership qualities, strategic vision, and a profound impact on their organisations and industries.
Discover Our Other Brands
Uncover our other brands, created and hosted by parent company AI Global Media, each with its own unique identity and specialised area of expertise. Our brands span a wide range of regions and sectors, covering business practice, technology, lifestyle, and more on a global scale. All of our brands reflect our commitment to diversity and innovation in content creation.
